Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
By F. Cappuzzo, F. Hirsch, E. Rossi, S. Bartolini, G. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini and 10 more. Journal of the National Cancer Institute, 2005
1,591 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/90fead5bb6058ccfb0e2832769d37923f455bb4a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
- J. Engelman
- P. Jänne
- James E. Bradner
- William Pao
- Andrew K. Joe
- Gwen Macdonald
- I. Weinstein
- G. Shapiro
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007, background): “To further complicate patient selection, recent correlative analysis suggests that in addition to EGFR/K-Ras mutational analysis, EGFR gene amplification and protein expression may also serve as important molecular markers (Cappuzzo et al., 2005).”
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy (2006, background): “Recent studies suggest that, in addition to point mutations in the gene encoding the EGFR, other factors could influence the sensitivity of NSCLC tumors to EGFR inhibitors, including EGFR gene amplification, the activation state of the EGFR protein, specific downstream signaling pathways, and phar”
- Comparing antibody and small-molecule therapies for cancer (2006, background): “In addition, more recent reports have indicated that other factors have a role in determining responsiveness to gefitinib in patients with NSCLC, including amplifications of EGFR and ERBB2 (Ref”
- PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. (2007, background): “Because PF00299804 is a pan-ERBB inhibitor and most EGFR mutant cell lines express multiple ERBB family members, the effects on EGFR phosphorylation could potentially be indirect (11, 28, 36).”